Int J Angiol 2016; 25(02): 093-098
DOI: 10.1055/s-0035-1563603
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Growth Rate of Small Abdominal Aortic Aneurysms and Genetic Polymorphisms of Matrix MetalloProteases-1, -3, and -9

Roberto Adovasio
1   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
,
Cristiano Calvagna
1   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
,
Giada Sgorlon
1   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
,
Francesca Zamolo
1   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
,
Filippo Mearelli
1   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
,
Gianni Biolo
1   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
,
Gabriele Grassi
2   Department of Life Sciences, University of Trieste, Trieste, Italy
,
Nicola Fiotti
1   Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
04 September 2015 (online)

Abstract

Genetic variants of matrix metalloproteases (MMPs)-1, -3, and 9, together with clinical variables, might predict the growth rate (GR) of abdominal aortic aneurysm (AAA). Genotyping of MMP-1 (−1,607 G+/G−), MMP-3 (− 1,171 6A/5A), and MMP-9 microsatellite (13–26 cytosine–adenosine repeats around -90) from peripheral blood was performed in 137 AAA patients with two AAA diameter measurements (at least 3 months to 1 year apart). When the same technique (either ultrasound or computed tomography) was used for the two measurements, yearly GR was estimated and compared with MMP genotype and clinical features by linear and binary logistic regression. Collectively, 36 patients provided 94 observations, with a median GR of 3 mm/year (interquartile range, 0–5.8); GRs in carriers of MMP-1 polymorphism G−/G−, G−/G+, and G+/G+ genotype were 0.3, 3.5, and 4.7mm/year, respectively (p = 0.008). In linear logistic regression, the main determinant of GR was growth arrest (GA, i.e., GR = 0, occurring in 32 observations, 34%). In turn, GA occurred mainly in G−/G− MMP-1 genotype (odds ratio, 3.9; 95% confidence interval, 1.6–9.7; p = 0.002), while variables accounting for GR > 0 were MMP-1 G + /G+ genotype, intake of any antihypertensive drug, and MMP-3 6A/6A genotype. Carriers of none, one, or two/three of these conditions accounted for a GR of 3, 4, and 9 mm/year, respectively (p = 0.001). MMP-1 (−1,607 G+/−) variant is associated to differential GR in AAA: homozygous G deletion variant shows higher GA prevalence and lower GR, while carriers of G + /G+ MMP-1 genotype, together with intake of antihypertensive drugs, and 6A/6A in MMP-3 present cumulative GR increase.